Ministry of health evaluates offering new dengue vaccine by SUS

The Ministry of Health is analyzing offering a new dengue vaccine through the Unified Health System (SUS). Baptized as Qdenga, the immunizer was approved by the National Health Surveillance Agency (Anvisa) on Thursday (2) and can be applied to the population between 4 and 60 years of age, both in people who have never had or have already developed the disease. turn.

“The inclusion of the vaccine to control dengue in the SUS is a priority”,

Ministry of health considers offering dengue vaccine through SUS

The analysis of the incorporation will be carried out by the National Commission for the Incorporation of Technologies in the Unified Health System (Conitec).

Another vaccine, called Dengvaxia, had already been approved by the agency, but its use was indicated only for people who had already been infected by the disease.

Anvisa will evaluate the efficacy, accuracy, effectiveness, safety and also the economic impact of the new technology. In its composition, the new vaccine contains four different serotypes of the virus that causes the disease. Qdenga has also already been approved for use and marketing in the European Union on December 20, 2022 and is produced by Japanese pharmaceutical company Takeda Pharma.

It showed an overall efficacy of 80.2% against the disease 12 months after the application of the second dose. The studies also indicated that Qdenga reduced hospitalizations by 90%.

Read more:

Disclosure of Bolsonaro card data violates the law, says Ministry of Health

Amazonas returns bariatric surgery in SUS patients

‘Vaccine Now’: More than 1,300 people were vaccinated against Covid-19 during the campaign